# entry[].resource.item[].item[].answer[].valueCoding.display
Ja, ich willige ein – weiter zur Befragung

# entry[].resource.item[].text
Are you requesting authorization for initial therapy or continuation of therapy? 

# entry[].resource.item[].item[].text
Does the patient have a diagnosis of migraine consistent with the International Classification of Headache Disorders?

# entry[].resource.item[].item[].answer[].valueCoding.display
Greater than or equal to 8 migraine days per month 

# entry[].resource.item[].item[].text
Has the patient experienced a trial and failure (after at least two months), contraindication, or intolerance to two standard prophylactic therapies (e.g., amitriptyline, beta-blockers, topiramate, etc.)? 

# entry[].resource.item[].item[].text
Alternatively, has the patient experienced a trial and failure (after at least three months), contraindication, or intolerance to two preventive therapies (e.g., Aimovig, Ajovy, Emgality, or an oral CGRP receptor antagonist)?

# entry[].resource.item[].item[].text
Will the medication be used in combination with another biologic CGRP antagonist or inhibitor used for the preventive treatment of migraines?

# entry[].resource.item[].item[].text
Is the dosing in accordance with the U.S. Food and Drug Administration (FDA) approved labeling?

# entry[].resource.item[].item[].answer[].valueCoding.display
Migraine without aura, intractable, with status migrainosus 

# entry[].resource.item[].text
Are you requesting authorization for initial therapy or continuation of therapy? 

# entry[].resource.item[].item[].text
Does the patient have a diagnosis of migraine consistent with the International Classification of Headache Disorders?

# entry[].resource.item[].item[].answer[].valueCoding.display
Greater than or equal to 8 migraine days per month 

# entry[].resource.item[].item[].text
Has the patient experienced a trial and failure (after at least two months), contraindication, or intolerance to two standard prophylactic therapies (e.g., amitriptyline, beta-blockers, topiramate, etc.)? 

# entry[].resource.item[].item[].text
Alternatively, has the patient experienced a trial and failure (after at least three months), contraindication, or intolerance to two preventive therapies (e.g., Aimovig, Ajovy, Emgality, or an oral CGRP receptor antagonist)?

# entry[].resource.item[].item[].text
Will the medication be used in combination with another biologic CGRP antagonist or inhibitor used for the preventive treatment of migraines?

# entry[].resource.item[].item[].text
Is the dosing in accordance with the U.S. Food and Drug Administration (FDA) approved labeling?

# entry[].resource.item[].item[].answer[].valueCoding.display
Migraine without aura, intractable, with status migrainosus 

# entry[].resource.text.div
Beispiel-QuestionnaireResponse zu http://rki.de/edz/demo_dkp|3.0

# entry[].resource.item[].answer[].valueCoding.display
**Ja**, ich willige ein – weiter zur Befragung

# entry[].resource.text.div
Beispiel-QuestionnaireResponse zu http://rki.de/edz/demo_dkp|3.0

# entry[].resource.item[].answer[].valueCoding.display
**Ja**, ich willige ein – weiter zur Befragung

# entry[].resource.item[].answer[].valueString
Ich fühle mich heute sehr gut und bereit für den Test.